European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene - Haas, M; Vlcek, V; Balabanov, P (Neuromuscul Disord, 2015)